Featuring an interview with Dr Sagar Lonial, including the following topics:
- Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00)
- Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15)
- Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00)
- Other investigational strategies for R/R MM (12:55)